Stereotactic body radiotherapy (SABR) for limited metastases
Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer
Samsung Medical Center · NCT07121335
This program tries stereotactic body radiotherapy (SABR) in people with up to five oligometastatic or oligoprogressive cancer lesions to see if it controls disease better, affects symptoms and side effects, and changes ctDNA in the blood.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Samsung Medical Center (other) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT07121335 on ClinicalTrials.gov |
What this trial studies
This is an observational cohort of patients with oligometastatic or oligoprogressive cancer who receive SABR to up to five lesions. Patients must have ECOG performance status 0–2 and imaging within four weeks confirming eligible lesions. Outcomes tracked include progression-free survival, local failure rate, physician-assessed toxicity, patient-reported outcomes, and serial circulating tumor DNA (ctDNA) dynamics. Data will be used to describe safety, clinical outcomes, quality-of-life changes, and potential ctDNA biomarkers associated with response.
Who should consider this trial
Good fit: Adults with metastatic cancer who have up to five oligometastatic or oligoprogressive lesions, ECOG 0–2, no prior radiotherapy to the planned SABR site, and imaging confirming lesions within four weeks are eligible.
Not a fit: Patients with prior radiotherapy to the planned treatment site or with concurrent brain metastases are excluded and unlikely to benefit from enrollment.
Why it matters
Potential benefit: If successful, the study could support use of SABR to improve local control and quality of life and help identify ctDNA signals that predict benefit.
How similar studies have performed: Randomized and cohort studies of SABR in oligometastatic disease have shown promising improvements in disease control and survival, while using ctDNA as a predictive biomarker remains novel and less established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Performance status (ECOG PS) 0-2 * Diagnosed with metastatic disease * Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions) Exclusion Criteria: * Patient with a history of prior radiotherapy to the site planned for SABR * Patients with concomitant brain metastases
Where this trial is running
Seoul
- Samsung medical center — Seoul, South Korea (RECRUITING)
Study contacts
- Study coordinator: Nalee Kim, MD, PhD
- Email: nalee.kim@samsung.com
- Phone: 82-2-3410-2612
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Stereotactic Body Radiation Therapy, Oligometastasis, Oligoprogression, ctDNA, Patient-Reported Outcomes, Stereotactic body radiotherapy